This is a preview of subscription content, log in via an institution to check access.
Références
Le Chevalier T, Brown A, Natale R, et al. Gemcitablne In the treatment of non-small cell lung cancer (NSCLC): a meta-analysis of survival and progression free survival data. Lung Cancer 2003; 41: 70
Schiller JH, Harrington D, Belani CP, et al. for the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8
Stewart LA, Parmar MK. Meta-analysis of the literature or of Individual patient data: is there a difference ? Lancet 1993; 341: 418–22
Scagliotti G, De Marinis F, Rinaldi M, et al. for the Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non small cell lung cancer. J Clin Oncol 2002; 20: 4285–91
Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage Mb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41(Suppl. 2): 65
Dunsford M, Mead GM, Bateman A, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10: 943–7
Kosmidis PA, Bacoyiannis C, Mylonakis N, et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis. Proc Am Assoc Clin Oncol 2000; 18: A1908
Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21: 3909–17
Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478
Treat J, Chandra BP, Edelman M, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage MB, IV) non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41(Suppl. 2): 64
Pujol JL, Breton JL, Riviere A, et al. Gemcitabine-docetaxel (GD) versus vinorelbine-cisplatin (VC) in advanced non-small cell lung cancer (NSCLC). A phase III study. Lung Cancer 2003; 41(Suppl. 2): 65
Mezger J, Pilz LR, Koschel G, et al. Single-agent gemcitabine (G) and docetaxel (D) given sequentially every 3 weeks in advanced NSCLC: final results and quality of life assessment of a randomised phase II study show effective treatment. Lung Cancer 2003; 41(S2): 64
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelloma. J Clin Oncol 2003; 21: 2636–44
Shepherd FA, Pereira JR, Von Pawel J, et al. A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy. Lung Cancer 2003; 41Suppl. 2: 4
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pujol, JL. Introduction. Am J Cancer 3 (Suppl 1), 1–4 (2004). https://doi.org/10.2165/00024669-200403991-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024669-200403991-00001